Depo-Provera Lawsuit Update January 2026: What the New FDA Warning Means for Depo Users
- Daniela P.
- Jan 2
- 9 min read
What Does the New FDA Warning Mean for Depo-Provera Lawsuits?
The FDA has approved a label change for Pfizer’s birth control shot Depo-Provera, adding a warning about meningioma brain tumors. This regulatory action, finalized in December 2025, comes as nearly 2,000 women have filed lawsuits against Pfizer, alleging the company knew about the brain tumor risk for decades but failed to warn American patients. The new label states that meningioma cases have been reported with repeated use and advises healthcare providers to monitor patients for signs and symptoms. How this affects the ongoing litigation—particularly Pfizer’s federal preemption defense—will become clearer as the case moves toward bellwether trials expected later this year.
Quick Summary: What You Need to Know
If you're short on time, here's what matters:
What happened | FDA approved a new Depo-Provera label warning about meningioma brain tumor risk in December 2025. |
Why it matters | This undermines Pfizer’s argument that it couldn’t be sued because the FDA previously rejected a warning label. |
How many lawsuits | Nearly 1,500 cases in federal court (MDL 3140), plus hundreds more in state courts. |
Scientific evidence | Studies show a 2.4x to 5.5x increased risk of brain tumors in long-term users. |
Who can file | Women who used Depo-Provera for over a year and were diagnosed with meningioma. |
Time limits | Generally, 2-3 years after diagnosis, but it varies by state—consult an attorney promptly. |
Next steps | Expert disclosures in early 2026; bellwether trials expected late 2026 or 2027. |
What Is the New FDA Warning for Depo-Provera?
The FDA approved a label update for Depo-Provera in December 2025 that now warns patients and healthcare providers about a potential link to meningioma brain tumors. The updated label states:
“Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma.”
The warning applies to both Depo-Provera CI (intramuscular injection) and Depo-SubQ Provera 104 (subcutaneous injection). The label also advises that the medication should be discontinued if a meningioma is diagnosed and that it is contraindicated in patients with a history of meningioma.
This marked the first time U.S. labels included any brain tumor warning for the popular birth control shot, which has been used since its FDA approval in 1992.
Why Did the FDA Previously Reject the Warning?
Pfizer’s path to the new warning label is central to the litigation. According to court filings, Pfizer says it became aware of meningioma risks in 2023 and submitted a label update request to the FDA in February 2024.
The FDA rejected that request, stating that “the findings of the available observational studies alone do not support the addition of a warning on Meningioma risk to medroxyprogesterone acetate (MPA)-containing products.”
Pfizer amended and resubmitted its application in June 2025 with additional data. The FDA approved the updated warning in December 2025.
This timeline matters because Pfizer has argued in court that it shouldn’t be liable for failing to warn patients since the FDA rejected its proposed warning. Now that the FDA has approved the warning, that defense may face new challenges—though the outcome will depend on how the court interprets the facts.
How Does This Affect the Depo-Provera Lawsuits?
The FDA’s approval of a meningioma warning is a notable development in the litigation. Here’s what it may mean for both sides.
Federal Preemption Defense Under Threat
Pfizer has argued that federal law blocks state-level failure-to-warn claims because the FDA previously declined to approve a brain tumor warning. The company’s position: it submitted data and proposed warning language, but the agency said no, so Pfizer should be shielded from lawsuits.
Plaintiffs’ attorneys have pushed back, arguing that Pfizer downplayed studies linking Depo-Provera to meningiomas, misled the FDA, and could have used the Changes Being Effected (CBE) pathway to update labels when safety concerns arose independently.
Now that the FDA has approved the warning, Pfizer’s preemption argument may be more difficult to maintain. A ruling from Judge M. Casey Rodgers on this issue was on hold pending the FDA’s labeling decision.
What the Label Change Means for the Litigation
The new label provides regulatory acknowledgment of the meningioma risk. Plaintiffs’ attorneys argue this supports their central claim that Pfizer should have warned consumers earlier. The label update also matches what regulators in Canada, the European Union, and South Africa did years ago. How courts ultimately weigh this development remains to be seen.
What Does the Science Say About Depo-Provera and Brain Tumors?
Several peer-reviewed studies have linked Depo-Provera use to an increased risk of meningioma.
March 2024 BMJ Study
A study in The BMJ found that women who used Depo-Provera for more than one year had a 5.5 times higher risk of developing intracranial meningiomas compared to non-users. The research analyzed data from over 108,000 women in France.
September 2025 Cleveland Clinic Study
Cleveland Clinic and Case Western Reserve University researchers published findings in JAMA Neurology after analyzing data from more than 10 million women across 68 U.S. healthcare organizations.
Key findings:
Women who used Depo-Provera had a 2.43 times higher relative risk of meningioma compared to non-users
Risk was highest in women who started injections after age 31
Risk increased in women who used the drug for more than four years
Other contraceptives showed no similar increased risk
The researchers calculated that one additional brain tumor would be expected for every 1,152 women exposed to Depo-Provera.
July 2025 Comparative Safety Study
A study in Expert Opinion on Drug Safety compared medroxyprogesterone acetate to ethinylestradiol-levonorgestrel (used in many oral contraceptives). Women using MPA for over a year were 3.5 times more likely to develop meningiomas.
How Many Depo-Provera Lawsuits Have Been Filed?
The Depo-Provera litigation grew quickly throughout 2025 and continues to expand.
Federal MDL
As of January 2026, nearly 1,500 lawsuits are pending in the federal MDL (No. 3140) in the Northern District of Florida before Judge M. Casey Rodgers. The case count has climbed fast:
78 cases in March 2025
348 cases in June 2025
806 cases in September 2025
Nearly 1,500 cases as of January 2026
The judge has scheduled monthly Case Management Conferences throughout 2026.
State Court Cases
Hundreds of additional cases are pending in state courts:
Delaware: 330+ plaintiffs
New York: 80+ plaintiffs
California: 20+ cases
Illinois: 6 cases
Pennsylvania, Connecticut, New Mexico: Additional cases pending
Legal experts expect thousands more claims as awareness grows.
What Is a Meningioma?
A meningioma is a tumor that develops in the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas (approximately 78-81%) are benign (non-cancerous), they can still cause serious health effects.
Symptoms of Meningioma
Depending on where the tumor forms, symptoms may include:
Persistent headaches
Vision changes or loss
Hearing loss or ringing in the ears
Memory problems
Seizures
Weakness in arms or legs
Balance difficulties
Speech problems
Treatment Options
Treatment for meningiomas may include:
Monitoring: Regular scans to track slow-growing tumors
Surgery: To remove all or part of the tumor
Radiation therapy: When surgery isn’t possible, or the tumor can’t be entirely removed
The cost of brain tumor treatment can reach hundreds of thousands of dollars, including surgery, hospital stays, rehabilitation, and ongoing monitoring.
Why Didn’t the U.S. Have a Warning When Other Countries Did?
A key allegation in the lawsuits: Pfizer warned patients in other countries about this risk while keeping American women in the dark.
2022-2024: The Canadian and European Union added meningioma warnings to Depo-Provera labels
January 2025: South Africa’s drug regulatory agency recommended adding meningioma risk to labels
December 2025: U.S. labels finally updated
Plaintiffs point out that studies linking Depo-Provera to brain tumors go back to 1983, when researchers found that synthetic hormones could stimulate progesterone receptors in meningioma tumors. They allege that Pfizer failed to investigate the risks or warn American consumers, despite decades of evidence.
Who May Qualify to File a Depo-Provera Lawsuit
You may have a case if:
✓ You received Depo-Provera, Depo-SubQ Provera 104, or authorized generic injections
✓ You used the birth control shot for more than one year
✓ You were later diagnosed with a meningioma brain tumor or spinal tumor
✓ You underwent surgery, radiation, or have treatment scheduled
Important: This litigation only covers meningioma tumors. Meningiomas are a specific type of tumor that forms in the meninges (the membranes surrounding the brain and spinal cord). Other types of brain tumors are not included in the current Depo-Provera lawsuits.
Not sure what type of tumor you have? Many people don’t know the specific name of their tumor. You can find this information in your medical records, pathology report, or by asking your doctor. The tumor type is typically listed in imaging reports (MRI or CT scan) or surgical/biopsy results. If your records say “meningioma,” you may qualify. If they list a different tumor type (such as glioma, acoustic neuroma, or pituitary adenoma), you would not qualify for this particular litigation.
You may still qualify even if:
You stopped using Depo-Provera years ago.
You didn’t know the shot caused your tumor until recently.
No criminal charges were filed against the manufacturer.
You used a generic version of the drug.
What Is the Statute of Limitations for Depo-Provera Lawsuits?
Most states give you 2-3 years to file a personal injury claim, usually starting from when you were diagnosed or when you reasonably should have connected Depo-Provera to your tumor.
These deadlines vary by state and can get complicated. Talk to an attorney sooner rather than later—missing the deadline could bar you from filing.
What Happens Next in the Depo-Provera Litigation?
2026 should bring key developments in this case.
Expert Disclosures and Depositions
The court has set deadlines for expert testimony on general causation (whether Depo-Provera can cause meningiomas):
January 1, 2026: Plaintiffs’ expert disclosures due
February 9, 2026: Defendants’ expert disclosures due
May 29, 2026: Briefings on motions to exclude experts completed
Mid-2026: Judge expected to rule on expert testimony motions
Bellwether Trials
Five cases have been selected as bellwether trials—the first to go before a jury. These test cases help both sides gauge how juries respond to the evidence and often drive settlement talks. Trials are expected in late 2026 or early 2027.
The five bellwether cases:
Blonski v. Pfizer: Plaintiff started Depo-Provera in 2002, diagnosed with meningioma after severe headaches and arm twitching, and later diagnosed with a second tumor
Wilson v. Pfizer: Plaintiff used Depo-Provera from 1998-2019, discovered Grade 1 meningioma after suffering a stroke
Toney v. Pfizer
Schmidt v. Pfizer
Arceo v. Pfizer
Potential Settlement
In most pharmaceutical mass torts, settlements follow bellwether trials that establish claim values. How the preemption ruling goes—and how early trials play out—will likely shape whether Pfizer moves toward a global settlement. Legal experts estimate payouts could range from $150,000 to $800,000+, depending on tumor severity and treatment.
Frequently Asked Questions
I had a brain tumor after using Depo-Provera, but I don’t know what kind. How do I find out?
Your tumor type should be listed in your medical records. Look for your pathology report, MRI or CT scan results, or surgical notes. You can also call your doctor’s office and ask what type of tumor you were diagnosed with. Only meningiomas are covered in this litigation—other brain tumor types (like gliomas, schwannomas, or pituitary tumors) are not included in the current lawsuits.
Can I file a Depo-Provera lawsuit if I only received a few injections?
Most cases require at least one year of use (four or more injections). But an attorney can look at your specific situation.
Does it matter if I used the brand name or the generic version?
No. Both brand-name Depo-Provera and authorized generics containing medroxyprogesterone acetate are covered. Some cases also name generic manufacturers as defendants.
How long will the Depo-Provera lawsuit take?
Mass tort cases typically take several years. Expert disclosures are happening in early 2026, with bellwether trials expected in late 2026 or early 2027. Settlements, if they happen, would follow. Timelines vary by case.
How much compensation might I receive?
No settlement amounts have been set yet. Compensation depends on your injuries, medical costs, lost wages, and pain and suffering. An attorney can give you a better estimate based on your situation.
Will I have to go to court?
Probably not. Most mass tort cases settle before trial. If your case is in the MDL, pretrial work is handled collectively—you likely won’t need to appear unless your case is picked for trial.
What if my meningioma was benign?
You may still have a claim. Even benign meningiomas can cause serious symptoms and require surgery or ongoing care.
Can I join the lawsuit if I’m still using Depo-Provera?
Yes, if you’ve been diagnosed with a meningioma and have a history of using Depo-Provera. That said, the FDA now advises stopping the medication if a meningioma is found.
We Can Help If You Developed a Brain Tumor After Using Depo-Provera
If you or someone you love was diagnosed with a meningioma after using the Depo-Provera birth control shot, you may have legal options. Click here to be connected with our team for a free, confidential case evaluation.
The FDA’s decision to require a brain tumor warning confirms what studies have shown for years—this birth control shot carries risks that American women weren’t told about. An attorney can help you understand whether you have a case and what your options might be.
Time limits apply, so don’t wait to learn about your rights.
Sources
NBC News, “FDA approves label change for Depo-Provera, adding brain tumor warning,” December 2025. nbcnews.com
STAT News, “FDA approves brain tumor warning on Depo-Provera label as court battle grows over side effects,” December 2025. statnews.com
U.S. News & World Report, “FDA Adds Brain Tumor Warning to Depo-Provera Birth Control Shot,” December 2025. usnews.com
Medscape, “Meningioma Warning Added to Depo-Provera Label,” December 2025. medscape.com
Medscape, “Contraceptive Tied to Higher Brain Tumor Risk in Women,” September 2025. medscape.com
FDA, Depo-Provera CI Prescribing Information, Revised December 2025. accessdata.fda.gov
Comments